Skip to main content

Postural Low Back Pain

2
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Ache Laboratorios Farmaceuticos
2 programs
2
Orphenadrine + Acetaminophen + Caffeine + Diclofenac SodiumPhase 3
orphenadrine, acetaminophen, caffeine and diclofenac sodiumPhase 31 trial
Active Trials
NCT02985671Unknown110Est. Oct 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Ache Laboratorios Farmaceuticosorphenadrine, acetaminophen, caffeine and diclofenac sodium

Clinical Trials (1)

Total enrollment: 110 patients across 1 trials

NCT02985671Ache Laboratorios Farmaceuticosorphenadrine, acetaminophen, caffeine and diclofenac sodium

To Evaluate the Superiority of Fixed Combination (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to Voltaren® (Diclofenac Sodium 50mg) in the Treatment of Acute Postural Low Back Pain.

Start: Jan 2021Est. completion: Oct 2021110 patients
Phase 3Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.